From patient assistance to clinical insight: applications and challenges of real-world data in drug development and patient care

In today's healthcare environment, Patient Assistance Programs (PAP) play a critical role: they not only help patients access expensive medicines but also provide valuable Real World Data (RWD) for clinical practice and drug development. This data complements traditional clinical trial evidence, enabling treatments to become more personalized and precise.

Patient assistance programs: data analysis that eases financial burdens and improves treatment outcomes

First and foremost, the core purpose of patient assistance programs is to relieve the financial burden patients face in accessing high-priced medicines. Through these programs, healthcare providers can collect large volumes of data on treatment outcomes, adverse events, and patient characteristics. This information not only deepens the understanding of how drugs work but also helps hospitals design more effective treatment plans for patients.

For example, the PatientsForce Data Science Lab team applies its data analytics expertise, combined with an understanding of pharmaceutical industry trends, to maximize the value of PAPs. Using PAP service data, the team analyzes clinical shifts in targeted therapy—including patients' Duration of Treatment (DOT) and changes in drug purchasing behavior—to observe market-wide declines in patients' ability to pay, informing how programs are optimized and adjusted.

The challenges of real-world data: controlling bias and safeguarding data security

The use of real-world data, however, has its limitations. Compared with carefully designed clinical trials, real-world data typically lacks sufficient controls and randomization, which can introduce bias and confounding factors that limit its ability to establish causality. Inconsistencies in how data is collected and processed can also affect its quality and reliability.

The ethical and regulatory challenges are equally significant. Patient assistance programs involve large amounts of sensitive personal health information, and its collection and use must strictly comply with ethical standards and regulatory requirements to protect patient privacy and data security. This requires hospitals and pharmaceutical companies to establish transparent data handling mechanisms and ensure patients' informed consent.

The evolution of patient support: from financial assistance to comprehensive care

To meet these challenges, hospitals can establish dedicated projects to systematically collect and analyze data from Patient Assistance Programs (PAP). Collaboration between patient support management companies and pharmaceutical companies can reduce the risk of pharmaceutical companies influencing medical diagnoses, while expanding the scope and depth of data collection and strengthening the monitoring of drug efficacy and safety. In addition, hospitals and patient support management companies should set clear policies governing the ethical collection and use of data, to preserve patient trust and comply with relevant regulations.

Over time, patient assistance has evolved from treatment initiation and financial support into a more comprehensive service portfolio—the Patient Support Program (PSP)—including but not limited to accompanying patients to appointments, disease and treatment education, and lifestyle guidance. Once a patient enters the treatment journey, the PSP further strengthens the quality and effectiveness of patient care. At the same time, stakeholders want to understand a treatment's real-world effectiveness and safety in order to clearly define its value.

Accordingly, the PatientsForce Data Science Lab team not only monitors patient adherence and treatment cycle changes across disease types, but also draws on expert knowledge of Taiwan's NHI prior authorization process and expands analyses of the reasonableness of regional patients' treatment cycles—reinforcing for internal and external stakeholders the value that PSPs and treatment bring to overall care outcomes.

Protecting privacy while improving care quality: the dual mission of patient support programs

Reliable data analysis in a Patient Support Program (PSP), however, depends first on addressing privacy and data confidentiality. PatientsForce can therefore provide solutions for ensuring data collection does not compromise the privacy of patients or healthcare providers. The Data Science Lab accesses only de-identified patient data, transferred securely from the PSP database to a secure analytics environment—enabling data analysis while safeguarding patient confidentiality.

Patient assistance programs are not only an effective tool for relieving patients' financial burdens; they are an indispensable resource for medical research and clinical practice. Through the scientific analysis and application of real-world data, we can substantially improve the quality of patient care and advance personalized medicine. But to ensure these resources are used effectively and responsibly, the accompanying ethical and practical challenges must be addressed.

─ April Li, PatientsForce Lead